Patents by Inventor Anaïs DOMINGOT

Anaïs DOMINGOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis and/or prognosis of HER2-dependent cancer using one or more miRNA as a biomarker
    Patent number: 11814685
    Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 14, 2023
    Assignees: UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
  • Treatment of HER-2 dependent cancer using an agent that modulates the activity of a miRNA
    Patent number: 11352627
    Abstract: This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: June 7, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
  • DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING ONE OR MORE MIRNA AS A BIOMARKER
    Publication number: 20200347457
    Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miR-NA 29a-3p, miRNA 29b- 3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
    Type: Application
    Filed: October 24, 2018
    Publication date: November 5, 2020
    Inventors: Sandrine BOURDOULOUS, Anaïs DOMINGOT, Camille FAURE
  • TREATMENT OF HER-2 DEPENDENT CANCER USING AN AGENT THAT MODULATES THE ACTIVITY OF A MIRNA
    Publication number: 20200339986
    Abstract: This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 29, 2020
    Inventors: Sandrine BOURDOULOUS, Anaïs DOMINGOT, Camille FAURE
  • DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING MOESIN AS A BIOMARKER
    Publication number: 20200308652
    Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of moesin in a sample from the subject; b) comparing the amount of moesin measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of moesin measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 1, 2020
    Inventors: Sandrine BOURDOULOUS, Anaïs DOMINGOT, Camille FAURE